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Introduction
Evidence suggests that early and aggressive treatment in
Juvenile Dermatomyositis (JDM) improves outcome and
prevents complications. Cyclophosphamide has been
used as a second-line agent in the treatment of severe or
refractory JDM. Published data on the effectiveness of
cyclophosphamide in JDM are limited to a previous small
case series and case reports.
Objectives
To describe the response to, and evaluate the effectiveness
of, intravenous cyclophosphamide in the patients with
JDM from the UK JDM National (UK and Ireland) Cohort
and Biomarker Study and Repository for Idiopathic
Inflammatory Myopathies.
Methods
The JDM National (UK and Ireland) Cohort and Biomar-
ker Study and Repository for Idiopathic Inflammatory
Myopathies (n = 410) prospectively collects clinical and
laboratory data and samples on all children recruited to the
study, using standardised protocols. 56 patients in the
cohort were treated with cyclophosphamide between 2000-
2011. Eight patients were excluded due to incomplete data
or short follow up. The remaining 48 had a diagnosis of
definite JDM, probable JDM or JDM overlap (Bohan and
Peter criteria), with a minimum of 12 months follow up
after the first dose of the cyclophosphamide. Demographic
data, core set measures of disease activity, skin data,
laboratory measures, treatment data were analysed at base-
line, 6, 12, 18, 24 months and last follow up.
Results
Indications for starting the cyclophosphamide were
ulcerative or severe skin disease, profound muscle weak-
ness, lung disease, gastro-intestinal vasculopathy or
refractory disease. All patients starting with muscle weak-
ness (n = 44) significantly improved at 12 months, and
the gains were maintained at follow up. Physician VAS
was available at baseline for 32 patients and these all
improved by 12 and 24 months, and for 31 remained
stable at follow up. At last follow up, 26/46 (56%) had no
rash, 32/46 (69%) had normal nailfolds, 37/45 (82%) had
no Gottron’s, and calcinosis has resolved in 9/14 (64%).
The steroid dose was decreased by 65.8% at 6 months,
and the majority of patients were off steroids or on very
low doses at 24 months. Patients receiving cyclophospha-
mide had a significant decrease in steroid dose by
6 months, with most of the patients coming off steroids
between 18 and 24 months.
Conclusion
These data suggest that cyclophosphamide provides clin-
ical benefit in JDM patients with severe or refractory
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